Urogen Pharma (URGN)
(Delayed Data from NSDQ)
$15.30 USD
-0.38 (-2.42%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $15.32 +0.02 (0.13%) 4:34 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Urogen Pharma falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 138 | 101 | 90 | 103 | 148 |
Receivables | 15 | 13 | 12 | 7 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 6 | 4 | 5 | 2 | 0 |
Other Current Assets | 10 | 11 | 7 | 3 | 1 |
Total Current Assets | 169 | 129 | 114 | 116 | 149 |
Net Property & Equipment | 1 | 1 | 2 | 2 | 1 |
Investments & Advances | 5 | 0 | 1 | 2 | 49 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 3 | 2 | 0 | 0 |
Total Assets | 178 | 136 | 120 | 122 | 202 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 17 | 12 | 12 | 10 | 11 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 8 | 7 | 10 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 3 | 3 | 2 | 2 |
Total Current Liabilities | 31 | 24 | 22 | 21 | 19 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 99 | 98 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 113 | 102 | 89 | 3 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 244 | 225 | 111 | 26 | 22 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 614 | 488 | 476 | 453 | 408 |
Retained Earnings | -679 | -577 | -467 | -357 | -228 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -65 | -89 | 8 | 96 | 180 |
Total Liabilities & Shareholder's Equity | 178 | 136 | 120 | 122 | 202 |
Total Common Equity | -65 | -89 | 8 | 96 | 180 |
Shares Outstanding | 23.40 | 22.70 | NA | 20.90 | 20.90 |
Book Value Per Share | -2.79 | -3.94 | 0.00 | 4.61 | 8.63 |
Fiscal Year End for Urogen Pharma falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 165 | 138 | 148 | 48 |
Receivables | NA | 14 | 15 | 13 | 16 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 7 | 6 | 5 | 5 |
Other Current Assets | NA | 10 | 10 | 16 | 13 |
Total Current Assets | NA | 197 | 169 | 182 | 81 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 5 | 7 | 8 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 2 | 2 | 3 |
Total Assets | NA | 201 | 178 | 194 | 95 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 18 | 17 | 14 | 16 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 5 | 11 | 8 | 7 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 3 | 4 | 4 | 4 |
Total Current Liabilities | NA | 26 | 31 | 26 | 27 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 98 | 99 | 99 | 98 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 113 | 110 | 108 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 241 | 244 | 236 | 234 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 671 | 614 | 611 | 493 |
Retained Earnings | NA | -712 | -679 | -653 | -631 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -40 | -65 | -42 | -138 |
Total Liabilities & Shareholder's Equity | NA | 201 | 178 | 194 | 95 |
Total Common Equity | 0 | -40 | -65 | -42 | -138 |
Shares Outstanding | 23.40 | 23.40 | 23.40 | 23.40 | 23.40 |
Book Value Per Share | 0.00 | -1.71 | -2.79 | -1.79 | -5.92 |